What Investors are Making of These Healthcare Stocks? - Antares Pharma, Globus Medical, NuVasive, and Insulet

Friday, June 24, 2016 Research News J E 4

NEW YORK, June 24, 2016 /PRNewswire/ --

Since the financial crisis, the Healthcare sector has proven to be defensive against market downturns, continuing to present opportunities for growth. Today's featured companies on belong in this arena: Antares Pharma Inc. (NASDAQ: ATRS), Globus Medical Inc. (NYSE: GMED), NuVasive Inc. (NASDAQ: NUVA), and Insulet Corp. (NASDAQ: PODD). Learn more about these stocks and receive your complimentary trade alerts at:  

To access full PDF Research Packages for free, please visit the links below.



(You may have to copy and paste the links into your browser)

ATRS Research Package:

GMED Research Package:

NUVA Research Package:

PODD Research Package:


Ewing, New Jersey headquartered specialty pharmaceutical Company, Antares Pharma Inc.'s stock finished Thursday's session flat at $1.01. A total volume of 1.63 million shares was traded, which was above their three months average volume of 776,250 shares. The Company's shares have advanced 16.09% in the past one month and 42.25% over the previous three months. The stock is trading above its 50-day moving average by 4.02%. Furthermore, shares of Antares Pharma, which focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies globally, have a Relative Strength Index (RSI) of 48.64.

On Thursday, shares in Audubon, Pennsylvania headquartered medical device Company, Globus Medical Inc., ended the session at $23.91, up 2.88%. The stock recorded a trading volume of 356,178 shares. The Company's shares have gained 1.01% in the last one month and 5.01% over the previous three months. The stock is trading 0.63% below its 50-day moving average. Moreover, shares of Globus Medical, which focuses on the design, development, and commercialization of musculoskeletal implants that promote healing in patients with spine disorders, have an RSI of 47.16.

San Diego, California headquartered medical device Company, NuVasive Inc.'s stock ended yesterday's session 1.85% higher at $58.86 with a total volume of 507,968 shares traded. The Company's shares have advanced 8.70% in the past one month, 26.25% over the previous three months, and 8.78% since the start of this year. The stock is trading 8.43% above its 50-day moving average and 17.34% above its 200-day moving average. Additionally, shares of NuVasive, which develops and markets minimally-disruptive surgical products and procedurally-integrated solutions for spine surgery, have an RSI of 64.85.

At the close on Thursday, shares in Billerica, Massachusetts headquartered medical device Company, Insulet Corp., recorded a trading volume of 572,649 shares. The stock finished 2.76% higher at $29.45. The Company's shares are trading below their 50-day moving average by 4.83%. Furthermore, shares of Insulet, which develops, manufactures, and sells insulin infusion systems for people with insulin-dependent diabetes in the U.S., have an RSI of 42.90.


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: Phone number:  +44 330 808 3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA



You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Epic Sciences Introduces Sensitive HRD Liquid Biop...
The AVA of Singapore Confirms Panda Chow Chows' We...